Download PDF
Klin Monbl Augenheilkd 2015; 232(5): 658-663
DOI: 10.1055/s-0035-1545829
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Therapie der okulären Graft-versus-Host-Erkrankung

Therapy for Ocular Graft-vs-Host Disease
P. Steven
1   Kompetenzzentrum Okuläre GvHD, Zentrum für Augenheilkunde, Uniklinik Köln
2   Exzellenzcluster: Cellular Stress Response in Aging Associated Diseases (CECAD), Universität zu Köln
,
L. Sauerbier
1   Kompetenzzentrum Okuläre GvHD, Zentrum für Augenheilkunde, Uniklinik Köln
,
S. Siebelmann
1   Kompetenzzentrum Okuläre GvHD, Zentrum für Augenheilkunde, Uniklinik Köln
,
U. Gehlsen
3   AG Augenoberfläche, Zentrum für Augenheilkunde, Uniklinik Köln
,
V. Tahmaz
3   AG Augenoberfläche, Zentrum für Augenheilkunde, Uniklinik Köln
,
S. Wittig
3   AG Augenoberfläche, Zentrum für Augenheilkunde, Uniklinik Köln
,
C. Scheid
1   Kompetenzzentrum Okuläre GvHD, Zentrum für Augenheilkunde, Uniklinik Köln
4   Stammzelltransplantationsprogramm, Klinik I für Innere Medizin, Uniklinik Köln
,
C. Cursiefen
1   Kompetenzzentrum Okuläre GvHD, Zentrum für Augenheilkunde, Uniklinik Köln
› Author Affiliations
Further Information

Publication History

eingereicht 28 January 2015

akzeptiert 17 February 2015

Publication Date:
19 May 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Therapie der okulären Graft-versus-Host Erkrankung (GvHD) stellt behandelnde Augenärzte häufig vor große Herausforderungen, da die Erkrankung oft rapide und nur schwer vorhersehbar verläuft. Primäres Therapieziel ist die Erhaltung oder Wiederherstellung des Sehvermögens, wobei aktuell nur wenige Studien zur Wirksamkeit der unterschiedlichen Verfahren verfügbar sind und zumeist Daten aus Studien zum Trockenen Auge mit anderen Ursachen vorliegen. Der Übersichtsartikel stellt die grundsätzlich verfügbaren Therapieansätze gegliedert nach lokaler, systemischer, operativer und prophylaktischer Option inklusive aktueller GvHD-Studien dar. Insgesamt existieren diverse lokale Therapien (Tränenersatzmittel, topisches Ciclosporin A etc.), systemische Verfahren (Immunsuppression, Photopherese etc.) und operative Maßnahmen, um die okuläre GvHD zu behandeln. Haupttherapieziele sind die Entzündungshemmung, die Antifibrose und die Oberflächenlubrikation. Obwohl in Konsensuskonferenzen Therapien empfohlen werden, sind Studien speziell zur GvHD unbedingt erforderlich, damit in Zukunft eine stadiengerechte Behandlung evidenzbasiert vorgenommen werden kann.

Abstract

Therapy for ocular graft-vs-host disease (ocular GvHD) is challenging for ophthalmologists as progress of the disease often occurs rapidly and is unforeseeable. Primary goal is the preservation or restoration of visual acuity, however, studies on ocular GvHD that have investigated therapeutic concepts are limited. In contrast, most therapeutic recommendations from consensus conferences derive from studies on dry eye diseases other than ocular GvHD. This review demonstrates the available therapies in the following categories: local, systemic, surgical and prophylactic. Primary targets are anti-inflammation, anti-fibrosis and lubrification of the ocular surface. In conclusion, studies strictly on ocular GvHD are needed to enable better evidence-based therapeutic decision-making in the future.

Schlüsselwörter

Bindehaut - Kornea - Kontaktlinsen - okuläre Graft-versus-Host Erkrankung (GvHD) - Serumaugentropfen

Key words

conjunctiva - contact lenses - cornea - ocular graft-vs-host disease (ocular GvHD) - serum eyedrops
 

  • Literatur

  • 1 Dietrich-Ntoukas T, Cursiefen C, Westekemper H et al. Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD. Cornea 2012; 31: 299-310
    CrossrefPubMedGoogle Scholar
  • 2 Couriel DR. Ancillary and supportive care in chronic graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21: 291-307
    CrossrefPubMedGoogle Scholar
  • 3 Laflamme MY, Swieca R. A comparative study of two preservative-free tear substitutes in the management of severe dry eye. Can J Ophthalmol 1988; 23: 174-176
    PubMedGoogle Scholar
  • 4 Sullivan LJ, McCurrach F, Lee S et al. Efficacy and safety of 0.3 % carbomer gel compared to placebo in patients with moderate-to-severe dry eye syndrome. Ophthalmology 1997; 104: 1402-1408
    CrossrefPubMedGoogle Scholar
  • 5 Tauber J. Efficacy, tolerability and comfort of a 0.3 % hypromellose gel ophthalmic lubricant in the treatment of patients with moderate to severe dry eye syndrome. Curr Med Res Opin 2007; 23: 2629-2636
    CrossrefPubMedGoogle Scholar
  • 6 Khaireddin R, Schmidt KG. [Comparative investigation of treatments for evaporative dry eye]. Klin Monatsbl Augenheilkd 2010; 227: 128-134
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Bernauer W, Thiel MA, Kurrer M et al. Corneal calcification following intensified treatment with sodium hyaluronate artificial tears. Br J Ophthalmol 2006; 90: 285-288
    CrossrefPubMedGoogle Scholar
  • 8 Yeh PT, Hou YC, Lin WC et al. Recurrent corneal perforation and acute calcareous corneal degeneration in chronic graft-versus-host disease. J Formos Med Assoc 2006; 105: 334-339
    CrossrefPubMedGoogle Scholar
  • 9 Kaden R. Verordnung von Tränenersatzflüssigkeiten – ein Gang durch den Paragraphendschungel. Z Prakt Augenheilkd 2012; 33: 449-450
    PubMedGoogle Scholar
  • 10 Khaireddin R, Hueber A. [Eyelid hygiene for contact lens wearers with blepharitis. Comparative investigation of treatment with baby shampoo versus phospholipid solution]. Ophthalmologe 2013; 110: 146-153
    CrossrefPubMedGoogle Scholar
  • 11 Guillon M, Maissa C, Wong S. Symptomatic relief associated with eyelid hygiene in anterior blepharitis and MGD. Eye Contact Lens 2012; 38: 306-312
    CrossrefPubMedGoogle Scholar
  • 12 Lindsley K, Matsumura S, Hatef E et al. Interventions for chronic blepharitis. Cochrane Database Syst Rev 2012; (5) CD005556
    PubMedGoogle Scholar
  • 13 Robinson MR, Lee SS, Rubin BI et al. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant 2004; 33: 1031-1035
    CrossrefPubMedGoogle Scholar
  • 14 Wang Y, Ogawa Y, Dogru M et al. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. Bone Marrow Transplant 2008; 41: 293-302
    CrossrefPubMedGoogle Scholar
  • 15 Dastjerdi MH, Hamrah P, Dana R. High-frequency topical cyclosporine 0.05 % in the treatment of severe dry eye refractory to twice-daily regimen. Cornea 2009; 28: 1091-1096
    CrossrefPubMedGoogle Scholar
  • 16 Jacobs DS, Rosenthal P. Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease. Cornea 2007; 26: 1195-1199
    CrossrefPubMedGoogle Scholar
  • 17 Stason WB, Razavi M, Jacobs DS et al. Clinical benefits of the Boston Ocular Surface Prosthesis. Am J Ophthalmol 2010; 149: 54-61
    CrossrefPubMedGoogle Scholar
  • 18 Takahide K, Parker PM, Wu M et al. Use of fluid-ventilated, gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease. Biol Blood Marrow Transplantat 2007; 13: 1016-1021
    PubMedGoogle Scholar
  • 19 Sauerbier L, Behr K, Moalem Y et al. Sklerallinsenversorgung bei okulärer Graft-versus-Host Erkrankung – Anpassung, Kostenübernahme, Nachkontrollen. Deutsche Ophthalmologische Gesellschaft. Leipzig 2014: PFr 04 – 08.
    PubMedGoogle Scholar
  • 20 Fox RI, Chan R, Michelson JB et al. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum 1984; 27: 459-461
    CrossrefPubMedGoogle Scholar
  • 21 Ogawa Y, Okamoto S, Mori T et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant 2003; 31: 579-583
    CrossrefPubMedGoogle Scholar
  • 22 Dietrich T, Weisbach V, Seitz B et al. [Manufacture of autologous serum eye drops for out-patient therapy : cooperation between ophthalmic clinic and transfusion medicine department]. Ophthalmologe 2008; 105: 1036-1038 1040–1042
    CrossrefPubMedGoogle Scholar
  • 23 Weisbach V, Dietrich T, Kruse FE et al. HIV and hepatitis B/C infections in patients donating blood for use as autologous serum eye drops. Br J Ophthalmol 2007; 91: 1724-1725
    CrossrefPubMedGoogle Scholar
  • 24 Sabti S, Halter JP, Braun Fränkl BC et al. Punctal occlusion is safe and efficient for the treatment of keratoconjunctivitis sicca in patients with ocular GvHD. Bone Marrow Transplant 2012; 47: 981-984
    CrossrefPubMedGoogle Scholar
  • 25 Ahmad SM, Stegman Z, Fructhman S et al. Successful treatment of acute ocular graft-versus-host disease with tacrolimus (FK506). Cornea 2002; 21: 432-433
    PubMedGoogle Scholar
  • 26 Jung JW, Lee YJ, Yoon SC et al. Long-term result of maintenance treatment with tacrolimus ointment in chronic ocular graft-versus-host disease. Am J Ophthalmol 2015; 159: 519-527
    CrossrefPubMedGoogle Scholar
  • 27 Ryu EH, Kim JM, Laddha PM et al. Therapeutic effect of 0.03 % tacrolimus ointment for ocular graft versus host disease and vernal keratoconjunctivitis. Korean J Ophthalmol 2012; 26: 241-247
    CrossrefPubMedGoogle Scholar
  • 28 Truitt RL, Johnson BD, Hanke C et al. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. J Immunol 1999; 163: 5145-5156
    PubMedGoogle Scholar
  • 29 DallʼAmico R, Murer L. Extracorporeal photochemotherapy: a new therapeutic approach for allograft rejection. Transfus Apher Sci 2002; 26: 197-204
    CrossrefPubMedGoogle Scholar
  • 30 Wolff D, Gerbitz A, Ayuk F et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010; 16: 1611-1628
    CrossrefPubMedGoogle Scholar
  • 31 Frucht-Pery J, Sagi E, Hemo I et al. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol 1993; 116: 88-92
    CrossrefPubMedGoogle Scholar
  • 32 Pfeffer I, Borelli C, Zierhut M et al. Treatment of ocular rosacea with 40 mg doxycycline in a slow release form. J Dtsch Dermatol Ges 2011; 9: 904-907
    PubMedGoogle Scholar
  • 33 Peris-Martinez C, Menezo JL, Diaz-Llopis M et al. Multilayer amniotic membrane transplantation in severe ocular graft versus host disease. Eur J Ophthalmol 2001; 11: 183-186
    PubMedGoogle Scholar
  • 34 Cursiefen C, Rummelt C, Beckmann MW et al. Amniotic membrane-covered bio-onlays for treatment of ocular surface disease. Br J Ophthalmol 2007; 91: 841-842
    CrossrefPubMedGoogle Scholar
  • 35 Nakamura T, Inatomi T, Sotozono C et al. Transplantation of autologous serum-derived cultivated corneal epithelial equivalents for the treatment of severe ocular surface disease. Ophthalmology 2006; 113: 1765-1772
    CrossrefPubMedGoogle Scholar
  • 36 Meller D, Fuchsluger T, Pauklin M et al. Ocular surface reconstruction in graft-versus-host disease with HLA-identical living-related allogeneic cultivated limbal epithelium after hematopoietic stem cell transplantation from the same donor. Cornea 2009; 28: 233-236
    CrossrefPubMedGoogle Scholar
  • 37 Kheirkhah A, Ghaffari R, Kaghazkanani R et al. A combined approach of amniotic membrane and oral mucosa transplantation for fornix reconstruction in severe symblepharon. Cornea 2013; 32: 155-160
    CrossrefPubMedGoogle Scholar
  • 38 Tarnawska D, Wylegala E. Corneal grafting and aggressive medication for corneal defects in graft-versus-host disease following bone marrow transplantation. Eye (Lond) 2007; 21: 1493-1500
    CrossrefPubMedGoogle Scholar
  • 39 Liu C, Okera S, Tandon R et al. Visual rehabilitation in end-stage inflammatory ocular surface disease with the osteo-odonto-keratoprosthesis: results from the UK. Br J Ophthalmol 2008; 92: 1211-1217
    CrossrefPubMedGoogle Scholar
  • 40 Schrage N, Hille K, Cursiefen C. [Current treatment options with artificial corneas: Boston Kpro, Osteo-odontokeratoprosthesis, Miro Cornea(R) and KeraKlear(R)]. Ophthalmologe 2014; 111: 1010-1018
    CrossrefPubMedGoogle Scholar
  • 41 Allan EJ, Flowers ME, Lin MP et al. Visual acuity and anterior segment findings in chronic graft-versus-host disease. Cornea 2011; 30: 1392-1397
    CrossrefPubMedGoogle Scholar
  • 42 Balaram M, Dana MR. Phacoemulsification in patients after allogeneic bone marrow transplantation. Ophthalmology 2001; 108: 1682-1687
    CrossrefPubMedGoogle Scholar
  • 43 Blecha C, Wolff D, Holler E et al. Korneale Komplikationen nach Kataraktoperation bei Patienten mit chronischer okulärer Graft-vs.-Host-Erkrankung nach allogener hämatopoetischer Stammzelltransplantation. Leipzig: Deutsche Ophthalmologische Gesellschaft; 2014: PFr05-05
    Google Scholar
  • 44 Malta JB, Soong HK, Shtein RM et al. Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05 %. Cornea 2010; 29: 1392-1396
    CrossrefPubMedGoogle Scholar